Previously, we have demonstrated that the IL-6/STAT3 signaling pathway plays a central role in mediating the resistance of rectal cancer to chemoradiotherapy (CRT) and that inhibition of IL-6/STAT3 signaling leads to the sensitization to CRT in vitro and in vivo [21,22]. Here, STAT3 is linked to rectal cancer.